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I INTRODUCTION 
The discovery of antimicrobial agents at the beginning of the last century was undoubtedly 
one of the most important milestones in the history of human and veterinary medicine alike. 
Soon after the first antibiotic was found by Alexander Fleming, researchers all over the world 
came up with descriptions of new drug classes. Yet, the awareness of the existence of drug 
resistant bacteria is as old as the knowledge about the benefits of antimicrobial treatment. For 
decades after Fleming’s discovery, this fact was deemed unimportant as new drugs became 
readily available any time an older drug was rendered incapable of action. In the last 30 years 
this attitude has changed due to the rising concerns about emergence and spread of resistance 
while the discovery of new classes of antimicrobial agents has slowed considerably. The 
study of resistance in bacteria has gained importance in many places and monitoring programs 
have been established both in human and veterinary medicine. The EU-wide ban of growth 
promoters in veterinary medicine was a direct outcome of the research focusing on 
antimicrobial resistance, as was the formulation of guidelines for prudent use of antimicrobial 
agents.  
The present doctoral thesis reports on the effect of an antimicrobial agent important to the 
dairy industry (ceftiofur) on a model organism: Escherichia coli. This organism has proven to 
be ideal for screening studies since it is easy to culture and generally present in large numbers 
in animal feces. It is not only important in its own right because of the potential to serve as a 
source of resistance determinants for bacterial pathogens, but also mirrors the effect of drugs 
on other bacterial species such as Salmonella.  
The objective of this work was to study the effect of ceftiofur on resistance of E. coli isolates 
obtained from dairy cow fecal samples. This was done by applying a screening method to 
large numbers of isolates in order to enable the investigators to pick up small effects that the 
drugs might have on the bacterial population and the epidemiology of antimicrobial 
resistance.  
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II LITERATURE OVERVIEW 
1 Antimicrobial agents 
Although many compounds used for treatment of bacterial disease in humans and animals are 
commonly referred to as antibiotics, the terms “antimicrobial agent” and “antibiotic” are not 
interchangeable. The term “antibiotic” refers to substances that are produced by 
microorganisms and that act on other microorganisms by selectively inhibiting their growth 
and even destroying them; it should not be used to indicate synthetic or semisynthetic 
compounds, substances of plant or animal origin, and substances active against animal cells 
(Guardabassi and Courvalin, 2006). 
1.1 The discovery of antimicrobial drugs in the 20th century 
At the beginning of the 20
th
 century, the German chemist and physician Paul Ehrlich, was 
systematically testing chemical agents, searching for the “magic bullet” that could be used as 
a medicine to fight infection. This effort resulted only in a potentially toxic arsenic-based 
treatment for syphilis (Goldsworthy and McFarlane, 2002).  
The discovery of penicillin and its publication in 1929 by the bacteriologist Alexander 
Fleming in London was a “fortunate occurrence” (after he left unclean culture plates with 
staphylococci in a corner while on holidays) as he described it in his 1945 Nobel prize lecture 
(Fleming, 1945). It is commonly considered as the start of antibiotic history, although 
Fleming himself considered lysozyme as the first antimicrobial agent he discovered, its 
antimicrobial action becoming clear to him when he accidentally sneezed on a Petri dish 
(Goldsworthy and McFarlane, 2002). 
Interestingly, Fleming used penicillin as an additive to culture media for differentiation of 
bacteria. Its use as an antibiotic drug for the treatment of infections in humans was established 
only when Ernst B. Chain and Howard Florey took up the investigation twelve years later. 
They were awarded the Nobel Prize in Medicine together with Alexander Fleming. 
Prior to widespread use of penicillin for disease treatment, another discovery earned a 
scientist the Nobel Prize in Medicine in 1939. Gerhard Domagk, a German pharmacologist, 
discovered that a dye used to tint cloth cured streptococcal infections in mice and the active 
compound sulfanilamide was identified shortly thereafter by Daniel Bovert, a Swiss-born 
II. Literature Overview 
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scientist (Khardori, 2006).  
Francis F. Schwentker was the first to report successful treatment of meningococcal 
meningitis in humans by subcutaneous and intraspinal injection of sulfanilamide (Schwentker 
et al., 1937). 
Another researcher contributed greatly to the beginnings of antibiotic history. Selman A. 
Waksman, a Russian-Jewish immigrant to the United States was investigating 
microorganisms when he came across a mold adhered to a clump of dirt, which had been 
taken from the neck of a sick chicken. When Waksman used the mold producing the antibiotic 
streptomycin against tubercle bacilli, the mold was able to kill the bacteria (Okonko et al., 
2008). In 1944, streptomycin was administered to a young woman who had advanced 
pulmonary tuberculosis and resulting in cure of the disease (Khardori, 2006). Waksman was 
awarded the Nobel Prize in Medicine in 1952. 
Since then a multitude of antimicrobials have been discovered, most of which are produced by 
actinomycetes and bacteria. Nowadays, most antimicrobial agents are chemically altered. 
Today, some 5,000 antibiotics are known but only about 1,000 of these have been carefully 
investigated and about 100 are currently used to treat infections in humans (Okonko et al., 
2008). The majority of antimicrobial drugs used in animals belong to a small number of major 
classes with the most important ones being beta-lactams, aminoglycosides, macrolides, 
lincosamides, chloramphenicol, tetracycline and sulfonamides. Only one class, namely 
fluoroquinolones, has been added in the last 30 years (Prescott, 2006). 
The introduction of antimicrobial drugs in veterinary medicine was similar to that in human 
medicine although their use as growth promoters has marked one of the major differences. 
The enhancement of growth rates and improved efficiency of feed were first noted when pigs 
and poultry were fed waste derived from an antibiotic production plant (Giguère, 2006). 
1.2 Antimicrobial mode of action  
There are five major mechanisms of action of antimicrobial drugs: inhibition of cell wall 
synthesis, damage to cell membrane function, inhibition of nucleic acid synthesis or function, 
inhibition of protein synthesis, and inhibition of folic acid synthesis. A short description of 
each of these mechanisms is included below to review how antimicrobial drugs interfere with 
biological processes in bacteria, together with examples of important antimicrobials in 
veterinary medicine.  
II. Literature Overview 
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1) Inhibition of cell wall synthesis: 
Multi-layered glycan and peptide strands form a peptidoglycan layer conferring 
mechanical protection and a solid surface for cell wall proteins (Guardabassi and 
Courvalin, 2006). It is considerably thicker in Gram-positive than in Gram-negative 
organisms where it is surrounded by an outer lipopolysaccharide layer, but it is also 
more permeable, allowing for larger molecules (such as beta-lactam antimicrobials) to 
pass (Tipper, 1985). 
The cell wall synthesis happens in three consecutive steps, namely the formation of 
muramyl pentapeptide in the cytoplasmic phase, the translocation of muramyl 
pentapeptide through the cell membrane (membrane-associated phase) and the cross-
linkage of glycan and peptide in the extracytoplamic phase (Guardabassi and 
Courvalin, 2006). 
Interference with cell wall function leads to lysis of the cell resulting in death of the 
bacterium. 
Beta-lactam drugs (e.g. penicillin or cephalosporins) target the enzymes responsible 
for joining glycan and peptide, the transpeptidases, better known as PBPs (penicillin-
binding-proteins) (Tipper, 1985). Glycopeptides (e.g. vancomycin, avoparcin) also 
inhibit the extracytoplamic phase by making the pentapeptide precursor unavailable to 
the PBPs by binding to acyl-D-alanyl-D-alanine (Reynolds, 1989). 
Bacitracin blocks the membrane-associated phase by forming a complex with the 
undecaprenyl pyrophosphate lipid carrier (Toscano and Storm, 1982). 
2) Damage to cell membrane function 
The cell membrane, which forms part of the cell wall of Gram-negative bacteria, acts 
as a sieve, and allows only small molecules to pass, in sharp contrast to the cell wall of 
Gram-positive bacteria (Decad and Nikaido, 1976). The polymyxins (e.g. polymyxin 
B, colistin) increase the permeability of the outer cell membrane of Gram-negative 
bacteria by binding to the lipopolysaccharides, destroying the barrier to noxious 
agents. Gram-positive cells are typically intrinsically resistant (Vaara, 2010). 
Drugs belonging to the family of aminoglycosides (e.g. gentamicin, amikacin, 
neomycin, streptomycin) not only act on protein synthesis but also increase membrane 
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permeability by drug induced disruption of Mg
2+
-bridges (Mingeot-Leclerq, 1999). 
The combination of those mechanisms is seen as the reason for bacteriocidal activity 
of these drugs since all other protein synthesis inhibitors only have bacteriostatic 
property (Jana and Deb, 2006). 
3) Inhibition of nucleic acid synthesis or function 
Fluoroquinolones (e.g. enrofloxacin, danofloxacin) target two enzymes that are 
essential for unzipping during replication and transcription and packing of DNA: 
topoisomerase II (DNA gyrase; an enzyme important for initiation of DNA 
replication) and topoisomerase IV (an enzyme acting at the end of replication so that 
segregation into daughter cells can occur), leading to fragmentation of the 
chromosome and cell death (Martinez et al., 2006). While older drugs of this family 
have a greater potency against toposiomerase II, newer ones have a more balanced 
activity against both (Hooper, 2000). 
Rifamycins (e.g. Rifampicin) inhibit protein transcription of DNA into mRNA by 
blocking the RNA polymerase; it continues to be used in the therapy of mycobacterial 
diseases (Tupin et al., 2010). 
4) Inhibition of protein synthesis 
Most antibacterial drugs inhibiting protein synthesis act as inhibitors of translation by 
binding to specific sites on the bacterial ribosome. Bacterial organisms have 70 S 
ribosomes that consist of 50 S and 30 S subunits.  
Aminoglycosides (e.g. gentamicin, amikacin, neomycin. streptomycin) and 
tetracyclines (e.g. oxytetracycline) inhibit ribosome function by binding to the smaller 
30 S subunit (Chopra and Roberts, 2001). Aminoglycosides have been shown to not 
only bind to the 30 S subunit of the ribosome and thereby leading to aberrant protein 
synthesis, but to also inhibit subunit assembly (Mehta, 2002). Tetracyclines inhibit the 
binding of the aminoacyl-tRNA to the mRNA ribosome complex. 
It is also possible that drugs that inhibit protein synthesis bind to the 50 S subunit in 
chloramphenicol (Xaplanteri et al., 2003) or macrolides (e.g. Erythromycin, Tylosin, 
Tulathromycin) (Zhanel et al., 2001). 
Apart from aminoglycosides, which also affect membrane permeability (see above), 
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all other classes of drugs acting on the ribosome are bacteriostatic. 
5) Inhibition of folic acid synthesis 
Prokaryotes are dependent on producing folic acid, a precursor in nucleic acid 
synthesis. 
Sulfonamides (e.g. sulfadimidine) and diaminopyrimidines (e.g. trimethoprim) act on 
different steps of the bacterial folic acid synthesis and therefore exhibit a synergistic 
effect when used together. Diaminopyrimidines are dihydrofolate reductase inhibitors 
while sulfonamides act as competitive inhibitors of 4-aminobenzoic acid. It is 
important to note that the half-life of trimethoprim is only 30 minutes in sheep, one 
hour in the adult bovine and goat, three hours in horses and dogs and seven hours in 
calves: therefore, monotherapy with trimethoprim is of little use in veterinary 
medicine (Kroker et al., 2002) and the effect of the combined drugs mostly attributable 
to the sulphonamide component. 
6) Other modes of action 
Nitroimidazoles (e.g. metronidazole) lead to strand breaks in bacterial and protozoal 
DNA under anerobic conditions by producing toxic metabolites through a reduction 
step (Van der Wouden, 2001). 
2 Antimicrobial resistance 
2.1 History of antimicrobial resistance 
“But I would like to sound one note of warning. Penicillin is to all intents and purposes non-
poisonous so there is no need to worry about giving an overdose and poisoning the patient. 
There may be a danger, though, in underdosage. It is not difficult to make microbes resistant 
to penicillin in the laboratory by exposing them to concentrations not sufficient to kill them, 
and the same thing has occasionally happened in the body. The time may come when 
penicillin can be bought by anyone in the shops. Then there is the danger that the ignorant 
man may easily underdose himself and by exposing his microbes to non-lethal quantities of 
the drug make them resistant.”  
Sir Alexander Fleming, Nobel Prize Lecture (1945) 
The knowledge of resistance is as old as the awareness that certain substances like penicillin 
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act as antimicrobials (Abraham, 1940). Because the first antimicrobial agents, excluding the 
synthetic sulfonamide drugs, were all identified or derived from natural products, resistance 
determinants were already present in the environments from which these agents originated 
(Bush, 2004). Bacteria collected between 1914 and 1950 (the Murray Collection) were found 
to be completely sensitive to antimicrobial agents, including sulfonamides that had been 
introduced in the mid 1930s (Hughes and Datta, 1983). 
The great discovery of streptomycin for treating tuberculosis was diminished by the rapid 
development of resistance by mutation of the target genes (Hawkey, 1998). 
In general, soon after the introduction of antimicrobial agents in veterinary medicine, bacteria 
resistant to antibiotics rapidly emerged while others have not developed resistance in spite of 
long term exposure (such as the susceptibility of Streptococcus agalactiae towards beta-
lactam antimicrobials; Aarestrup and Schwarz, 2006). The importance of the spread of 
antimicrobial-resistant bacteria from food animals to humans became gradually more and 
more recognized during the 1950s and 1960s. For decades, the strategy to deal with bacteria 
resistant to the applied drugs was the development of new classes of antimicrobials. 
2.2 Antimicrobial resistance in human and veterinary medicine 
“Use of antibiotics in food-production animals has resulted in healthier, more productive 
animals: lower disease incidence and reduced morbidity and mortality in humans and 
animals: and production of abundant quantities of nutritious, high-quality, and low-cost food 
for human consumption. In spite of these benefits, there is considerable concern from public 
health, food safety, and regulatory perspectives about the use of antimicrobials in food-
production animals.” 
Stephen P. Oliver (2011) 
Infections caused by resistant bacteria are associated with higher morbidity and case fatality 
rate than those caused by susceptible pathogens and the occurrence of genes coding for 
antimicrobial resistance in a bacterial pathogen can have a pronounced negative impact on 
humans and animals alike (Helms et al., 2002). For all antimicrobials currently known in 
veterinary and human medicine, antimicrobial resistance mechanisms have been reported. 
In a Danish study, the investigators compared 2-year case fatality rates of patients infected 
with Salmonella Typhimurium with the mortality in the general Danish population. Death 
rates were 2.3 times higher when compared to the general population in cases where 
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Salmonella strains were pan-susceptible, 4.8 times higher if the strain was multi-drug resistant 
and 10.3 times higher if the bacteria showed resistance to quinolones (Helms et al., 2002). 
Travers and Barza (2002) report a relationship between antimicrobial resistance in Salmonella 
and Campylobacter with excess days of hospital stay and diarrhea in patients in the United 
States and consider the administration of antimicrobials to food animals as the source of 
resistance. Other authors reported a higher rate of hospitalization during disease outbreaks 
with antimicrobial-resistant Salmonella strains compared to outbreaks with pan- susceptible 
strains (22 % vs. 8 %) (Varma et al., 2005). Niederman (2001) concludes that excessive 
length of therapy and reconvalescence, higher death rates and higher cost is attributable to one 
important mechanism: the likelihood that initial empirical therapy will be inadequate in 
patients who are infected with resistant organisms. He points out the importance of collecting 
regular microbiological data to be able to make an educated choice on treatment. 
Multi-drug resistant bacteria can be present in a population of animals without leading to 
increased morbidity or mortality (Kaneene et al., 2010). However, their presence may also 
significantly change survival or cure rates of animals when infection occurs (Craven et al., 
2010; Giguere et al., 2010). 
While some authors clearly emphasize the evidence of antimicrobial-resistant bacteria, which 
lead to infections in humans, and their animal origin as foodborne pathogens (e.g. Swartz, 
2002), another view is that “almost every case made for or against antibiotics in animals is 
complicated by the use of the same antibiotics in humans, which are equally able to give rise 
to resistance” (Phillips et al., 2004). 
Yet, although direct harm to humans is hard to prove in general, the connection between drug-
resistant bacteria of food animal origin and illness in humans has been documented in detail in 
some cases (Spika et al., 1987; Fey et al., 2000) and that selection of resistant bacteria in 
animals has a potentially deleterious effect on human health. Also, introduction of such an 
organism of animal origin may be a very rare event in humans, but a phase of amplification in 
the human population through use of antimicrobials may exacerbate the problem (Turnidge, 
2004). 
No doubt exists that antimicrobial resistance is a problem in both veterinary and human 
medicine alike, and this has led to the establishment of monitoring programs on the 
antimicrobial resistance in bacteria of animal and human origin.  
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The Danish Integrated Antimicrobial resistance Monitoring and Research Programme 
(DANMAP) established in 1995 reports yearly on the surveillance of antimicrobial resistance 
in bacteria from livestock, food, and humans. DANMAP also collects data about bacteria 
producing extended spectrum beta-lactamase (ESBL), an enzyme that is responsible for 
bacterial resistance towards a broad range of beta-lactam antimicrobials (including all 
generations of cephalosporins). Its 2009 report states: “The parallel increase in prevalence in 
ESBL-producing bacteria in both humans and animals indicates that antimicrobial selection 
takes place in both reservoirs, and food-derived spread of ESBL-production E. coli may be 
the origin in at least part of the human cases.” (DANMAP, 2009). 
A similar surveillance program exists in the United States of America: The National 
Antimicrobial Resistance Monitoring System (NARMS) was built by joining forces of the 
FDA (United States Food and Drug Administration), the USDA (United States Department of 
Agriculture), and the CDC (Center of Disease Control) (Mathew et al., 2007). 
2.3 Types and dissemination of resistance encoding genes 
There are two classes of resistance: intrinsic and acquired. 
Intrinsic resistance in bacteria is defined as the “lack of cellular mechanisms required for 
antibiotic action” (Boerlin and White, 2006). Among many examples is the resistance of most 
Gram-negative bacteria toward penicillin since the size of the molecules does not allow the 
antimicrobial to pass the outer membrane. 
Acquired resistance: The influence of an antimicrobial chemical substance on bacteria can 
encourage them to obtain new genes by horizontal gene transfer or can lead to mutation of the 
bacterial genome encoding for resistance. Horizontal gene transfer and mutation can “act in a 
synergistic way because horizontal gene transfer introduces new alleles into a population and 
mutation produces new variations of these alleles” (Blazquez, 2003). Genetic mutations often 
lead to structural changes in the organism, while horizontal gene transfer usually codes for 
enzymes that enhance metabolization of antimicrobials. 
Unlike intrinsic resistance, acquired resistance does not have to be associated with all strains 
of a particular bacterial genus or species (Guardabassi and Courvalin, 2006). 
2.3.1  Horizontal gene transfer in bacteria 
Horizontal gene transfer describes the exchange of DNA between different bacterial cells as 
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opposed to vertical gene transfer from mother to daughter cell. Prokaryotes are dependent on 
rapid access to new genetic material in order to adapt to different environments and stressors. 
One such stressor can be the exposure to antimicrobial drugs.  
Microbes typically use one of the following methods for horizontal gene transfer: conjugation, 
transduction and transformation (Frost et al., 2005; Tenover, 2006).  
Conjugation requires cell-to-cell contact and the setting up of a conjugation pore to exchange 
genetic information in the form of plasmids (Kelly et al., 2009). The process is sometimes 
initiated by the induction of sex pheromones by the mating pair (Tenover, 2006). This transfer 
may occur between bacterial strains of the same species, within species of the same genus but 
also those belonging to different families.  
Transduction describes a bacteriophage-mediated process of transfer. It was first described by 
Zinder and Lederberg (1952) when they were studying genetic exchange in Salmonella 
species. Bacteriophages are viruses capable of infecting  bacterial host cells (Sorensen et al., 
2005). They typically have limited host range. There are two forms of bacteriophages, 
depending on their life cycle. Lytic: reproducing themselves while destroying their host; and 
lysogenic: being able to integrate themselves into the host´s genome (Kelly et al., 2009).  
Transformation is defined as the stable uptake, integration and functional expression of 
extracellular “naked” DNA that can occur under natural bacterial growth conditions (Thomas 
and Nielsen, 2005). 
2.3.2 Mobile genetic elements 
The above mentioned mechanisms transfer plasmids and other mobile genetic elements such 
as transposons and integrons.  
The term plasmid was first used by Lederberg and defined as “a generic term for any 
extrachromosomal hereditary component” (Lederberg, 1952). Plasmids are extra-
chromosomal, self-replicating genetic elements that are not essential to survival. The R-
factors found in enteric bacteria are quite complex plasmids carrying antibiotic resistance 
genes, but also encode for transfer functions allowing a rapid transmission within a population 
of related Gram-negative organisms (Normark and Normark, 2002). Plasmid-mediated 
resistance is also common in Gram-positive bacteria. For example benzyl-penicillin resistance 
achieved by the production of beta-lactamase in Staphylococcus aureus is mediated by the bla 
gene carried on plasmids (Normark and Normark, 2002). 
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Transposons (also called “jumping genes”) can move from one location on the chromosome 
to another or from plasmid to plasmid and create phenotypically significant mutations. This is 
the reason why some identical transposons can be found on many different plasmids of 
different species and origins. The first transposons were discovered in corn (Zea mays) by 
Barbara McClintock in 1948 for which she was awarded the Nobel Prize in Medicine in 1983 
(McClintock, 1950) . 
They can also function as conjugative transposons in the sense that they excise from and 
integrate into DNA like transposons but that they also have a covalently closed circular form 
for transfer via conjugation in the same way as for plasmids (Salyers et al., 1995).  
Insertion sequences (IS) are simple forms of transposons containing only those genes required 
for transposition (lacking genes encoding for antibiotic resistance or other traits) but that 
result in mutations due to their translocation (Mahillon and Chandler, 1998). 
The integron (gene cassette) system provides another powerful mechanism for the 
acquisistion of new genes and hence the evolution of bacterial genomes (Hall and Collis, 
1995; Recchia and Hall, 1995). Each cassette contains a single gene. Although any typical 
gene can be part of a cassette, for a long time most genes known to be found in integrons were 
resistance genes (Hall et al., 1999). Integrons are also frequently included in transposons. 
Recently, researchers have described another possibility. The so-called gene transfer agents 
(GTA) are “virus-like particles that only carry random pieces of genome of the producing cell 
in a process similar to generalized transduction” (Lang and Beatty, 2007). 
2.3.3 Mutation 
Compared to gene transfer, the generation of new genetic material by mutation is known to 
happen much more slowly. On the other hand, Blázquez (2003) showed that under selective 
pressure (such as in the case of exposure to antimicrobial drugs), mutator strains are favored 
over strains that are nonmutant. As many as 1% of E. coli and Salmonella natural isolates are 
already stable strong-mutators (those with a very high mutation rate) (Matic et al., 1997). 
Mobile genetic elements such as plasmids are also subjected to genetic alterations by 
mutations (Normark and Normark, 2002). Although most mutations in bacteria are non-
specific and happen “naturally”, Kohanski and others (2010) recently demonstrated that the 
influence of sublethal levels of antibiotic treatment induce mutagenesis due to bacterial 
production of reactive oxygen species and leading to higher mutation rates in treated 
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compared to untreated E. coli. 
Certain bacterial species, such as Mycobacterium tuberculosis, have an extremely low 
capability to exchange DNA with their surroundings, therefore resistance to antimycobacterial 
drugs is generally the consequence of spontaneous mutations (Normark and Normark, 2002). 
2.4 Mechanisms of resistance in bacteria 
Antimicrobial resistance mechanisms can be classified into the following categories: 
1) The antimicrobial agent can be prevented from reaching its target by reducing its 
penetration into the bacterial cell: 
Mutations leading to loss, reduction in size, or decreased expression of porins in the 
bacterial cell membrane are a mechanism of acquired, generally low-level resistance 
to various antibacterial agents (Guardabassi and Courvalin, 2006). Reduced uptake is a 
clinically important mechanism of resistance to beta-lactams and fluoroquinolones in 
Gram-negative bacteria, especially in Pseudomonas aeruginosa and 
Enterobacteriaceae (Guardabassi and Courvalin, 2006). Gram-negative bacteria are 
coated by an outer membrane which serves as a substantial permeability barrier. This 
fact explains, at least in part, the enhanced resistance of those bacteria compared with 
Gram-positive organisms (Vaara and Nurminen, 1999).  
Biofilm formation by some pathogenic bacteria such as P. aeruginosa has been 
discussed as a mechanism for drug resistance by reducing the penetration of 
antimicrobials into the cell (Normark and Normark, 2002). Other authors argue that 
the degree of susceptibility is not different from the one expressed by the same 
bacteria in a non-biofilm (planctonic) mode of growth (Spoering and Lewis, 2001). 
2) General or specific efflux pumps may expel antimicrobial agents from the cell: 
Resistance is determined by reduction in the concentration of the drug in the 
cytoplasm, preventing or limiting access of the drug to its target (Guardabassi and 
Courvalin, 2006). Drug-specific efflux mechanisms are generally encoded by plasmids 
and/or other mobile genetic elements that carry additional resistance genes. This 
explains their association with multidrug resistance (Poole, 2005). They can either be 
activated by environmental stimuli or by a mutation in a regulatory gene. Efflux 
pumps were first described for the mechanism of tetracycline resistance (Levy, 2002). 
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So-called multi-drug efflux systems have been described which provide resistance to a 
broad range of structurally unrelated antimicrobials and biocides (e.g. triclosan) 
(Poole, 2002). 
3) The antimicrobial agent can be inactivated by modification or degradation, either 
before or after penetrating the cell: 
Enzymatic inactivation is the main mechanism of resistance to beta-lactams, 
aminoglycosides, and phenicols. The most widespread and clinically important 
enzymes are the beta-lactamases and the aminoglycoside-modifying enzymes 
(Guardabassi and Courvalin, 2006). 
4) The antimicrobial target may be modified so that the antimicrobial cannot act on it 
anymore, or the microorganism´s acquisition or activation of an alternate pathway 
may render the target dispensable: 
This mechanism is particularly important for resistance to penicillins (for example 
methicillin resistance in Staphylococcus aureus, target site: peptidoglycan precursors), 
glycopeptides, and macrolides (target site: ribosome) in Gram-positive bacteria and for 
resistance to quinolones (target site: DNA gyrase and topoisomerase IV) in both 
Gram-positive and Gram-negative bacteria (Poole, 2002; Guardabassi and Courvalin, 
2006).  
A transpeptidase with low affinity for methicillin (PBP2A) partially replaces the 
normal transpeptidase (PBP2) in methicillin-resistant S. aureus (MRSA) containing 
the mecA gene. Changing the structure of the ribosome binding site is usually due to 
methylation by genetically acquired methylases and less common due to mutation of 
the target nucleotide sequence.  
The modification of target enzyme sequence in quinolones is due to mutation 
(Guardabassi and Courvalin, 2006). 
5) Drug Trapping or Titration: 
Bacteria may resist a drug by increasing the production of the drug target or another 
molecule with affinity for the drug. In both cases, the organism accomplishes a 
reduction in the proportion of target sited affected by the drug (titration) (Guardabassi 
and Courvalin, 2006). 
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2.5 The cost of resistance 
A higher mutation rate is associated with loss of fitness as mutators accumulate deleterious 
mutations more frequently than non-mutators (Chopra et al., 2003). Mutations and alterations 
of the bacterial genome through horizontal gene transfer harbor the danger of leading to 
reduction or even loss of viability, so that these cells may be at a disadvantage compared with 
the parent and may therefore be displaced from the population in the absence of antibiotic 
selection. Giraud et al. (1999) were able to show that strains experimentally selected for high-
level fluoroquinolone resistance had reduced fitness and were not selected in vivo in the 
absence of selective pressure. It is also clear that the replication of plasmids (which frequently 
carry the genes encoding for resistance) is costly and “if it were always favorable to be 
resistant, resistance to naturally occurring antibiotics would be ubiquitous” (Wassenaar, 
2005). Some mutants, however, do not lose fitness compared to their parents and will clearly 
be at an advantage in the case of antibiotic use which leads to their selection over non-
resistant strains. 
Therefore, an organism that has no fitness cost on account of being resistant will behave as 
any susceptible bacterial clone within a population and will rapidly expand if antibiotic 
selection pressure is exerted (Normark and Normark, 2002). 
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3 Implications of resistance in veterinary and human medicine 
“Everyone using antimicrobial drugs, including those in agriculture, shares the blame for the 
rise of resistance and the burden to use these drugs responsibly.” 
John F. Prescott (2006) 
The use of antimicrobials in veterinary medicine and its potential effect on resistance in 
bacteria has led to the establishment of surveillance programs, scientific investigations, and 
debates.  
Concerns have risen about drug-resistant pathogens originating from an animal related source 
(foodborne infections, direct contact) as well as bacteria of human origin acquiring resistance 
genes through gene transfer from these organisms and causing infections that are difficult to 
treat. Antimicrobial therapy of disease will be less effective if the underlying organism is 
resistant to the drug used. Antimicrobials that are used frequently in veterinary medicine and 
that are of the same class of drugs or even identical to the ones used in human medicine, as 
well as those that are the source of transferred genetic material coding for multi-drug 
resistance, are in the focus of these concerns.  
Following this thought, several questions are important to consider when discussing the topic 
of antimicrobial resistance in veterinary medicine:  
 Who is responsible to monitor antimicrobial resistance in animal and human 
pathogens?  
 Are antimicrobials or classes of antimicrobials used in veterinary and human medicine 
frequently identical?  
 Are bacterial organisms of animal origin a major source of resistance encoding genes 
in human pathogens? 
 What can be done to minimize and optimize antimicrobial usage both in human and 
veterinary medicine?  
 And what are strategies for alternative treatment of bacterial infections and in what 
way can treatment be reduced by preventing disease in animals? 
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3.1 Monitoring antimicrobial resistance 
The first major review of the effect of antimicrobial drug use on resistance in human and 
animal pathogens was carried out in the United Kingdom under the chairmanship of M.M. 
Swann and reported in 1969: “The administration of antibiotics to farm livestock, particularly 
at sub-therapeutic levels, poses certain hazards to human and animal health” and the authors 
recommended research into alternative means of growth promotion as well as improved 
surveillance programs (The Swann Report; Swann, 1969). 
Many surveillance programs have been instigated since then. Among the major ones are the 
National Antimicrobial Resistance Monitoring System (NARMS), which was established in 
1996 in the United States, the Canadian Integrated Program for Antimicrobial Resistance 
Surveillance (CIPARS), and the Danish Integrated Antimicrobial resistance Monitoring and 
Research Programme (DANMAP). These three include data from livestock, foods and 
humans. The European Antimicrobial Resistance Surveillance Network (EARS-Net), which 
became part of the European Centre for Disease Prevention and Control (ECDC) on January 
1
st
 2010, reports data on seven major human pathogens. The European Food Safety Authority 
(EFSA) publishes an annual European Union report on zoonoses, food-borne outbreaks and 
antimicrobial resistance.  
Surveillance data often are in the form of antibiograms originating from human or veterinary 
medicine that are used to compare isolates in both populations. One problem with this method 
is that results are not comparable because of various MIC definitions used to describe the 
particular subpopulations (Wassenaar and Silley, 2008). 
Yet, reports of surveillance programs are indispensable for providing data on the prescribing 
of antibiotics for physicians and veterinarians alike and are able to define areas where detailed 
supervision needs to be enacted (as in the example of increased extended spectrum beta-
lactamase (ESBL) producing bacteria). 
3.2 Overlap of antimicrobials used in veterinary and human medicine 
Although individual antimicrobial drugs have been specifically developed for use in 
veterinary or human medicine only (e.g. ceftiofur in animals and cefotaxime in humans, both 
belonging to the class of 3
rd
 generation cephalosporin drugs), most major classes of drugs are 
used in both human and veterinary medicine (Moulin et al., 2008). Classes of drugs solely 
used in veterinary medicine include feed additives such as ionophores, quinoxalines or 
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bambermycins (Collignon et al., 2009). When studying antimicrobial consumption in France, 
Moulin et al. (2008) found that four antimicrobial classes were accounting for 80% of sales in 
veterinary medicine (tetracyclines, sulphonamides/trimethoprim, beta-lactams and 
aminoglycosides) whereas beta-lactam antimicrobials dominated in human medicine 
(accounting for more than 50% of the total consumption). As an example of overlapping use, 
clinicians often treat Salmonella infections in humans with cephalosporin or fluoroquinolone 
antimicrobials and both classes of drugs are frequently administered to animals (Collignon et 
al., 2009). Emborg and co-authors (2001) conclude that “…it has proven almost impossible to 
maintain this distinction between antimicrobials used for animals as antimicrobial growth 
promoters (AGP) and those used as human therapeutics. Because of the increasingly limited 
therapies for humans – and with new technical possibilities for drug design – pharmaceutical 
companies have developed many old AGPs into drugs for human use. Some of these drugs 
(vancomycin, quinopristin/dalfopristin) are considered essential for the treatment of serious 
life-threatening infections in humans”. As an answer to the problem, the World Health 
Organization (WHO) has developed criteria in order to rank them according to their 
importance for the treatment of disease in humans (Tollefson et al., 2006). The list was 
created based on certain criteria and needs to be updated regularly; nevertheless it will be 
helpful in prioritizing the reduction in usage of certain classes of antimicrobials in veterinary 
medicine. Categories applied to the antimicrobial classes are “critically important”, “highly 
important” and “important” since all were found to be at least important in human medicine.  
The following definitions are taken from Tollefson et al. (2006):  
Critically important:  Antimicrobial drugs which meet BOTH WHO criteria 1 and 2. 
Highly important: Antimicrobial drugs which meet EITHER WHO criterion 1 or 2. 
Important: Antimicrobial drugs which meet EITHER WHO criterion 3 
and/or 4 and/or 5. 
WHO Criteria: 
1. Antimicrobial drugs used to treat enteric pathogens that cause food-borne disease. 
2. Sole therapy or one of few alternatives to treat serious human disease or drug is essential 
component among many antimicrobials in treatment of human disease. 
Serious diseases are defined as those with high morbidity or mortality without 
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proper treatment regardless of the relationship of animal transmission to humans. 
3. Antimicrobials used to treat enteric pathogens in non food-borne disease. 
4. No cross-resistance within drug class and absence of linked resistance with other drug 
classes. 
Absence of resistance linked to other antimicrobials makes antimicrobials more 
valuable. 
5. Difficulty in transmitting resistance elements within or across genera and species of 
organisms. 
Antimicrobials to which organisms have chromosomal resistance would be more 
valuable compared to those antimicrobials whose resistance mechanisms are 
present on plasmids and transposons. 
Among the classes  ranked “critically important” were  aminoglycosides, cephalosporins (3rd 
and 4
th
 generation), glycopeptides, macrolides, penicillins and quinolones (Collignon et al., 
2009), all of which are also used in veterinary medicine. 
A classification to define critically important antimicrobial agents in veterinary medicine is 
currently being prepared by the World Organization for Animal Health (formerly Office 
International des Épizooties) (Collignon et al., 2009). 
3.3 Source of resistance encoding genes in human pathogens 
Wassenaar (2005) argues that “most resistance developing in pathogens posing a serious risk 
to human health, are the result of human application rather than veterinary use of 
antimicrobials”. One bacterium accounting for serious problems with drug resistance in 
humans, prolonged hospital stay, treatment failure and death is methicillin-resistant 
Staphylococcus aureus (MRSA). After the first strain of MRSA was isolated in 1961 and only 
two years after the introduction of methicillin, MRSA spread to many countries within the 
next decade (Robinson and Enright, 2004). Vancomycin had been the treatment of choice for 
infections with this pathogen but a recent report describes how a MRSA isolate acquired 
resistance to vancomycin yet retaining its MRSA phenotype (called VRSA) through 
conjugative plasmid transfer from Enterococcus faecalis while a patient was treated 
repeatedly with this drug (Weigel et al., 2003). It is one of the examples of a multi-drug-
resistant pathogen that, after having evolved and spread in the human population, might pose 
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a danger to major domestic animal species (Cohn and Middleton, 2010).  
In contrast, an example of resistance developing in a foodborne pathogen is Campylobacter. 
Fluorquinolone-resistant Campylobacter infections in humans increased after the introduction 
of ciprofloxacin for human use and enrofloxacin in the poultry industry (Endtz et al., 1991). 
In countries where fluoroquinolones were not legalized for application in poultry medicine, a 
rise in resistance towards this class of drugs was not reported (Osterlund et al., 2003). 
Resistance is conferred by a single mutation in the gyrA gene (Wassenaar, 2005).  
A study on human and chicken E. coli isolates resistant to ciprofloxacin showed that resistant 
human isolates were distinct from susceptible human isolates but largely indistinguishable 
from chicken isolates implying a high possibility that they originate from the same source 
(Johnson et al., 2006). 
3.4 Prudent antimicrobial usage 
3.4.1        Human medicine 
In most countries, patients will receive (systemic) antimicrobial treatment only after seeing a 
doctor first. Although the physician might come to a different opinion after a physical 
examination, a survey showed that 48% of patients expected a prescription for antibiotics 
when feeling sufficiently ill from “a common cold” to seek medical attention (Vanden Eng et 
al., 2003).  
Also, self-medication with antibiotics occurs in many countries where over-the-counter drug 
sale is legal or minimally supervised (Grigoryan et al., 2006) or when leftovers are available 
to the individual from a previous course of prescribed treatment.  
From another study carried out by Grigoryan et al. (2008),  the authors concluded that 
interventions aiming to prevent self-medication should include the implementation and 
enforcement of laws for dispensing of antibiotics and expressed a specific concern about the 
lack of public education; awareness about antibiotic resistance was the lowest in countries 
with higher prevalence of resistance (Finch, 2004; Grigoryan et al., 2007). 
Education of the public and prescribing physicians will become more and more important to 
reduce unnecessary use of antimicrobial drugs in human medicine especially when it is 
already facing bacterial strains that have gained multi-drug resistance. 
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3.4.2         Veterinary medicine 
There are several different uses of antimicrobials in veterinary medicine: therapeutic use, 
prophylaxis, metaphylaxis and use of antimicrobials as growth promoters. 
Mercer et al. (1971) described the relationship between feeding cattle and swine antimicrobial 
agents as growth-promotors and the higher incidence of multi-drug resistant E. coli isolates in 
1971. In 1986, Sweden was the first country to ban the use of antimicrobial growth promoters 
in Europe. The growth-promoting use of bacitracin (a polypeptide antimicrobial), spiramycin, 
tylosin (both macrolide antimicrobials) and virginiamycin (streptogramin antimicrobial) was 
banned in the EU in 1999 because of the Precautionary Principle (Phillips, 2007). The use of 
avoparcin had been banned in the EU since 1997 and a EU-wide ban of the use of the last four 
antimicrobials as growth promoters in animal feed (monensin, salinomycin, avilamycin, 
flavophospholipol) came into effect on January 1
st
, 2006 (EC/1831/2003), marking the end of 
the phase-out process. Reduction of resistance in the pathogens belonging to the genera 
Enterococcus and Campylobacter was the target of the new legislation because they are the 
only major food-borne bacteria susceptible to the selected antimicrobials (Phillips, 2007). 
Prevalence of resistance towards spiramycin, tylosin and virginiamycin in indicator bacteria 
such as Enterococcus faecium was shown to have decreased rapidly since the ban (Bywater et 
al., 2005). There was no marked change in resistance of E. faecium from pigs (Denmark, The 
Netherlands, Spain, Sweden) and chickens (France, The Netherlands, Sweden, UK) towards 
bacitracin, but enterococci had been shown to be intrinsically resistant. This was shown by 
results from Sweden where it had not been used for many years (Phillips, 2007).  
It seems logical that the decreased resistance in indicator bacteria after the ban of growth 
promoters can only be an advantage for animals and humans alike. 
Nevertheless, for some observers a benefit for human health by reducing the number of 
infections with vancomycin-resistant enterococci after the ban of avoparcin (also a 
glykopeptid antimicrobial) as a growth-promotor in 1996 remains “not apparent, unless it is 
argued that the increases in incidence, escalating almost ten years after the ban, might have 
been still greater” (Phillips, 2007). It was argued that “the diminution of the resistance pool in 
animal and human fecal commensal enterococci has been at the cost of a deterioration in 
animal welfare” (Casewell et al., 2003) and led to a temporary rise in the use of 
antimicrobials for therapeutic reasons as was seen in the Swedish example (Wierup, 2001). 
Apart from reducing the amount of antimicrobial agents as growth promoters, the prudent use 
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of these drugs as therapeutic agents and for metaphylactic reasons plays a key role in trying to 
minimize consumption in veterinary medicine to a minimum. 
Recommendations for clinicians on how to use antimicrobials responsibly, includes the 
“guidelines for the careful handling of antibacterial veterinary drugs” (“Leitlinien für den 
sorgfältigen Umgang mit antibakteriell wirksamen Tierarzneimitteln”), that have been 
developed in Germany by the working committee on veterinary drugs (Arbeitsgruppe 
Tierarzneimittel) (BTK, 2010). The guidelines that have recently been published in an 
updated version offer information about antimicrobial usage (such as indication, treatment 
length, dosage, choice of drug) as well as more specified information on treatment for certain 
animal species.   
It is the responsibility of each veterinarian prescribing drugs to make sure that he or she is 
aware of the necessary information on how to use antimicrobials judiciously and to reduce 
their application to a scientifically validated minimum. 
3.5 Alternatives to antimicrobial treatment 
The “Golden Age” of antimicrobial discovery has long passed. In the last 35 years very few 
novel antimicrobial drug classes were found (Taylor and Wright, 2008). It has become 
increasingly more difficult for scientists to come up with new, safe, and chemically stable 
drugs to make up for those becoming useless due to increasing resistance of pathogens. 
Analyzing whole genome data of actinomycetes, screening large quantities of novel and 
potentially useful natural compounds, revisiting “old” substances that were discarded in the 
last century for several reasons, exploring marine actinomycetes or development of 
completely synthetic antibiotics have been the focus of researchers in order to supply the 
market with new antimicrobial agents (Taylor and Wright, 2008). 
Yet, in the light of what we now know about transfer and spread of resistance, it is clear that 
each new class will eventually be rendered incapable of fighting certain pathogens. 
Therefore, alternative approaches for treating bacterial infections in humans and animals are 
being investigated.  
3.5.1        Phage therapy 
One such alternative is the rediscovery of phage therapy. The concept of treating infections 
with lytic bacteriophages is not new and was discovered by Twart and d´Herelle at the 
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beginning of the 20
th
 century. The introduction of pencillin and other antibiotics shortly 
thereafter led to decreased interest in phage therapy (Johnson et al., 2008). Phages are 
abundant in nature and share a common ecology with their hosts (Bruessow, 2005). They are 
relatively specific to their target, mostly offering a greater specificity than antimicrobial 
drugs. When present at a specific ratio of phages to their bacterial host, phages can amplify 
themselves and kill the target host by repeated cycles of replication (Johnson et al., 2008). A 
multitude of studies can be consulted by the interested reader on this re-emerging approach 
(Sulakvelidze et al., 2001; Payne and Jansen, 2003; Fischetti, 2005; Higgins et al., 2005; 
Wagenaar et al., 2005; Gill et al., 2006; Callaway et al., 2008). In summary, phage therapy 
has shown potential for the control of animal and zoonotic pathogens in cattle, pigs and 
poultry, however, the studies showed the need for further investigation about candidate 
phages, efficacy, safety, administration routes and phage resistance (Johnson et al., 2008). 
3.5.2        Disease prevention 
The growth-promoter ban has made it essentially clear that preventing disease in livestock 
through prophylactic measures is necessary when reducing the amount of antimicrobials used 
in animals. 
The most extreme and safest way to prevent a bacterial infectious disease is by eradication of 
the disease-causing organism. Although eradication schemes to control for example bovine 
tuberculosis and brucellosis have lead to success in many countries, it is hard to reach 
eradication of a bacterial organism on a country-wide basis as has been achieved for several 
viral diseases (foot and mouth disease, classical swine fever). 
Control of bacterial diseases is easier to achieve on a herd basis. Examples are specific 
pathogen free (SPF) production of swine under strict biosecurity measures which have been 
established on a large-scale basis in some countries such as Denmark (Wierup, 2000) and 
Johne´s disease eradication programs.  
Clearly, optimizing hygiene and housing (e.g. ventilation, temperature) conditions in animal 
production, isolating sick animals from neighboring animals and maintaining closed herds 
(ideally also applying an “all in, all out” system) in combination with vaccination programs 
individually tailored to the farm level will have a marked effect on animal health and reduce 
the need to treat infections (Wierup, 2000; Potter et al., 2008). Concurrently, in human 
medicine, the need to encourage new vaccine development and to promote the principles of 
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infection control and effective hygiene within hospitals and among the community should be 
highlighted (Finch, 2004). 
It becomes clear that antimicrobial therapy is – and should always have been – just one way to 
deal with pathogenic bacteria. 
4 Antimicrobial susceptibility testing 
When choosing an antimicrobial drug to treat disease in humans and animals, it is 
fundamental to take several factors into account, including intrinsic or documented acquired 
resistance of the pathogen. Walker (2006) also includes the nature of the infection, the 
identity of the pathogen, the pharmacokinetic behavior of the chosen drug in the target animal 
species, the pharmacodynamic indices of the drug at the site of infection, host characteristics, 
cost, ease, route and frequency of administration as well as residue avoidance time in food 
animals. Yet, in individual cases the clinician will have to rely on culture results to determine 
which bacteria (if any) are to be blamed for the disease and in most cases treatment needs to 
be administered before having the culture information. Antimicrobial susceptibility testing 
(AST) has gained utmost importance in recent years due to increasing antimicrobial 
resistance. To study the influence of antimicrobials on bacterial populations, AST has also 
been used in numerous screening studies to learn about the status quo (Dunlop et al., 1998; 
Jordan et al., 2005; Jiang et al., 2006; Tragesser et al., 2006; Frye and Fedorka-Cray, 2007; 
Edrington et al., 2008; Lundin et al., 2008) or to study evolution of resistance in a target 
bacterial species over time (Lowrance et al., 2007; Singer et al., 2008; Alali et al., 2009). 
Several methods are suitable for AST such as disc diffusion, agar dilution, broth micro- and 
macrodilution, PDM Epsilometer test (E test) (Schwarz et al., 2010). 
Regardless of the test method selected, the routine application of quality control (QC) is an 
essential component of the AST and allows the laboratory to verify that its personnel, 
incubation conditions, test media, and antimicrobial agents are performing at an acceptable 
level (Watts, 2006). 
Since the first description of reduced antimicrobial susceptibility of a Staphylococcus species 
around the growth of a penicillin-producing mould by Alexander Fleming in 1929 (Fleming, 
1980) clinicians and researchers have faced the problem of the lack of standards for testing 
procedures, documentation of results and differences in reported resistance breakpoints 
(Bywater et al., 2006). In order to solve standardization issues, several institutes in the United 
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States and Europe have published guidelines for AST procedures including the Clinical and 
Laboratory Standards Institue (CLSI; formerly called National Committee for Clinical 
Laboratory Standards NCCLS)), the British Societey for Antimicrobial Chemotherapy 
(BSAC), the Deutsches Institut für Normung e.V. (DIN) and the Comité de la Société 
Française de Microbiologie (CA-SFM) (Schwarz et al., 2010). 
5 E. coli as a model organism for studying Salmonella 
Escherichia coli, commonly abbreviated as E. coli, is one of the most widely studied 
organisms today. Since its discovery by the German pediatrician Theodor Escherich in 1885, 
this Gram-negative rod-shaped bacterium has been used in science worldwide as a model for 
other prokaryotes (Shulman et al., 2007). Because of its wide application in research, it was 
the first organism to be suggested for whole genome sequencing; the complete genome was 
published in 1997 (Blattner et al., 1997). Besides its abundance in the environment, E. coli is 
easy to culture and stable laboratory strains have been developed (for example ATCC 
authenticated microoganisms, (ATCC, 2011). As the name suggests, this bacterium resides in 
the intestinal tract of warm blooded organisms (caudal small intestine and large intestine, 
(Selbitz, 2002) and is commonly found in the feces of animals and humans (about 10
4
 to 10
7
 
cfu/g manure in cattle). It is therefore used as an indicator of fecal contamination (Edberg et 
al., 2000). Lederberg (Lederberg and Tatum, 1946) discovered that the organism is not only 
able to reproduce asexually but also by sexual methods and can therefore be used for genetic 
studies. E. coli is classified as a so-called open pan-genome organism allowing for many 
opportunities of genetic exchange (Kelly et al., 2009). Studies of resistance in E. coli have 
lead to a better understanding of the relationship between the degree of antimicrobial drug use 
and the extent of resistance (Smith, 1975). Furthermore, standardized procedures for in- vitro 
susceptibility testing of E. coli are readily available 
While salmonellosis is still the most common reported food-borne bacterial disease in the 
United States today with 7,000 reported cases in 2008 (CDC, 2010), it is now second to 
Campylobacteriosis in the European Union with 131,468 confirmed cases in the same year 
(Lahuerta et al., 2010). These numbers may greatly underestimate the true extent of disease 
caused by pathogenic Salmonella serotypes and numbers have been estimated to be as high as 
1.4 million cases per year in the United States (Mead et al., 1999). 
Although many cases of salmonellosis are self-limiting and require no treatment, is is critical 
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to treat invasive human salmonellosis cases as the infection can lead to serious disease or even 
death, especially in the elder and in children. Concerns have risen that the emergence of 
antimicrobial resistance in this pathogen may be compromising the chance of recovery in 
severely ill patients.  
Because of the nature of naturally occurring infections with this bacterium (acute and chronic 
infections, intermittent shedding, seasonal dynamics) as well as demanding sampling and 
culturing conditions, in-vivo clinical trials are rare. Because of the ease with which E. coli can 
be obtained both from the environment and as a standardized organism, the simplicity of 
culturing and storing it, the great possibility of gene transfer and interaction within the species 
itself and with other bacterial species and the evidence of resistance gene transfer between 
those two species (Winokur et al., 2001), we used this prokaryote as a model to observe 
effects of antimicrobial drugs on resistance in Salmonella.  
Moreover, the colon of animals provides a rich opportunity for transfer of resistance between 
commensals and pathogens that is not available in the environment (Rollins et al., 1974). This 
lead us to study E. coli from fecal material. 
Measurement of the antimicrobial resistance status of whole populations of bacteria using 
standard techniques is problematic since these methods are adapted to small numbers of 
isolates in clinical settings. A technique is needed to assess large numbers of isolates in order 
to measure small effects that may have biological significance. In this study we applied a 
mass-screening technique to address the impact of ceftiofur use in dairy cattle. 
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1 Abstract 
The objective of this longitudinal controlled trial was to determine the effect of systemic 
treatment with ceftiofur on antimicrobial susceptibility of fecal Escherichia coli isolates in 
dairy cows. 
Cows with metritis or interdigital necrobacillosis requiring systemic antimicrobial treatment 
were sequentially assigned to two treatment groups. The first group was treated with ceftiofur 
hydrochloride and the second with penicillin G procaine. Untreated healthy control cows were 
selected for sampling on the same schedule as treated cows. Fecal samples were collected on 
days 0, 2, 7, 14, 21 and 28. 
21983 E. coli isolates from 42 cows were analyzed for susceptibility to ampicillin, 
tetracycline and ceftiofur using a hydrophobic grid membrane filter system to assess growth 
on agar containing selected antimicrobial drugs. Temporal changes in both the concentration 
of E. coli in feces and the susceptibility of E. coli to each drug were analyzed. A significant 
decrease in the concentration of fecal E. coli on days 2 and 7 post-treatment (but not 
thereafter) was detected in animals treated with ceftiofur. The proportion of all isolates (95% 
confidence interval in parentheses) showing reduced susceptibility at day 0 was 3.0% (2.5, 
3.6) for ampicillin, 10.6% (9.7, 11.6) for tetracycline, and 4.8% (4.2, 5.6) for ceftiofur; 1.7% 
(1.3, 2.1) of isolates were resistant to ceftiofur based on growth at 8 μg/ml. Treatment did not 
have any significant effect on the proportion of isolates expressing reduced susceptibility to 
antibiotics with the exception of decreased tetracycline susceptibility in the ceftiofur treated 
group on day 2. Although we found the potential for selection pressure by documenting the 
change in E. coli concentration following ceftiofur treatment, an increase in ceftiofur 
resistance was not found. 
2 Keywords 
Antimicrobial resistance, reduced susceptibility, E. coli, ceftiofur, hydrophobic grid 
membrane, dairy cow 
3 Introduction 
Treating livestock with antimicrobial drugs regarded as important in human medicine is a 
contentious issue. Concern arises because of the potential to select resistance in zoonotic 
pathogens. There are also fears that commensal bacteria exposed to antibiotics might develop 
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and propagate genetic elements coding for resistance that are subsequently acquired by human 
pathogens (Angulo et al., 2004; Wassenaar, 2005). One drug of concern is ceftiofur, a third 
generation cephalosporin. Systemic use of ceftiofur against common diseases of dairy cows is 
attractive because milk from treated individuals need not be withheld from marketing and 
withholding periods for meat are short (Tragesser et al., 2006). In human medicine, third 
generation cephalosporins are valued for treating serious or life threatening infections. 
Therefore, the use of ceftiofur in dairy cows is seen as a potential threat to the ability to cure a 
range of life-threatening infections in people (Allen and Poppe, 2002). There are special 
concerns about zoonotic forms of multi-drug resistant Salmonella acquiring resistance to third 
generation cephalosporins because dairy cattle are one of the reservoirs for these pathogens 
(Frye and Fedorka-Cray, 2007; Whichard et al., 2007). In response to these issues the United 
States Food and Drug Administration recently evaluated whether ceftiofur use should be 
modified to further protect consumers (FDA, 2009).  
Escherichia coli often is used as a model for changes in other bacterial species such as 
Salmonella because of similarities in their microbial physiology, frequently identical genetic 
determinants of resistance and similar mechanisms of genetic dissemination (Lowrance et al., 
2007). Several studies showed that the blaCMY-2 gene is responsible for cephalosporin 
resistance in both Salmonella and E. coli isolates (Donaldson et al., 2006; Daniels et al., 
2009). It is also likely that many resistance genes can be exchanged within the family of 
Enterobacteriaceae (Neuwirth et al., 2001). For every Salmonella bacterium in the intestine 
of humans and animals there are thousands of E. coli, subject to the same antimicrobial 
selection and capable of carrying and spreading the same or similar genetic resistance 
elements (O'Brien, 2002).  
Our objective was to scan large numbers of isolates to determine whether systemic ceftiofur 
or penicillin treatment of dairy cows under field conditions resulted in changes in 
antimicrobial susceptibility of fecal E. coli.  
4 Materials and Methods 
4.1 Study population and design 
We enrolled cows from two New York State dairy herds in a longitudinal controlled trial. 
Herd sizes were 140 and 300 milking cows. The dominant breed was Holstein-Friesian; all 
other cows were Ayrshires. A herd survey filled out by the owners showed that antimicrobial 
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usage practices for these herds were similar to those reported for conventional farms by 
Zwald et al. (2004). Ceftiofur was used on both farms prior to the study for typical purposes 
such as treatment of respiratory disease, metritis, retained placenta, and foot problems. 
Lactating cows with metritis or interdigital necrobacillosis as identified by the herd owner or 
veterinarian were enrolled sequentially in one of two treatment groups; ceftiofur or penicillin. 
The treatment for the first animal within each herd was selected at random. Healthy animals 
served as untreated controls and were paired with antibiotic-treated animals, alternating 
groups, and matching calving date and parity whenever possible. 
Samples were collected from each animal at enrollment (day 0) and subsequently five times in 
a four-week period. The target sampling days were 2, 7, 14, 21 and 28 days after enrollment. 
The study was conducted between July 2008 and July 2009. 
4.2 Treatment protocol 
Treatment for cows in the ceftiofur group consisted of a subcutaneous injection of 1 gram of 
ceftiofur hydrochloride suspension (Excenel RTU, Pharmacia & Upjohn Co, Division of 
Pfizer Inc, New York, NY) once per day for a total of four days. Cows enrolled in the 
penicillin group received 9 million IU of a penicillin G procaine suspension (PenOnePro, Vet 
One, MWI, Meridian, ID) intramuscularly once per day for a total of four days. 
4.3 Sample collection and processing 
Fecal samples were collected before treatment by the herd owner or veterinarian (day 0) and 
on days 2, 7, 14, 21 and 28 after enrollment by the veterinarian. Approximately 50 g of feces 
were collected directly from the rectum of each cow with a clean plastic sleeve. Samples were 
placed immediately into a sterile sample container and transported refrigerated to the 
laboratory to be processed on the day of collection.  
Those administering treatments and collecting samples were not blinded to treatment group. 
Study personnel carrying out laboratory procedures were unaware of the assignment of 
animals. 
Fifteen g of fecal material from each sample were placed in a sterile Whirl-Pak filter bag 
(Nasco, Fort Atkinson, WI) and mixed with 40ml of a sterile 0.9% saline solution. The sample 
was then mixed in a stomacher for 2 minutes. The filtrate was placed in a second sterile 
Whirl-Pak filter bag and processed for another 2 minutes. Five 1 ml replicates of the specimen 
were aseptically transferred from the filter pocket into 5 ml freezer vials prepared with 1 ml of 
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glycerol (Fisher Scientific, Fair Lawn, NJ) and tryptose soy broth (Becton, Dickinson and 
Company, Franklin Lakes, NJ) (1:1 vol/vol) and placed in a -80°C freezer for storage. 
4.4 Production of hydrophobic grid membrane filter master grids 
HGMF master grids were used to enumerate and replicate bacteria using a modification of a 
method described previously (Dunlop et al., 1998; Jordan et al., 2005). A master grid 
containing no more than 200 colonies was chosen to limit the probability of any one colony 
being derived from more than one bacterium (Jordan et al., 2005). 
To generate a master grid, each frozen sample was thawed in a 30 °C water bath. Five-fold 
serial dilutions were made in 0.1 % peptone water containing 1% Tween 80 (Fisher Scientific, 
Fair Lawn, NJ). Approximately 1.5 ml of each diluted sample was filtered through a sterile 
HGMF grid (ISO-GRID®, QA Life Sciences, CA) using an SF-1 Spreadfilter (Filtaflex, 
Almonte, Ontario, Canada). 
HGMF grids were then aseptically transferred onto MacConkey agar (MAC) (Northeast 
Laboratory Services, Waterville, ME) and incubated at 37°C for 18-24 h to produce a master 
grid (see Figure 1).  
If the dilution process failed to produce a grid as described, another replicate of the sample 
was chosen, thawed and more extended dilutions carried out until the condition was met. In 
cases where the diluted sample yielded very low numbers of colonies, either the sample was 
enriched in GN broth (Hajna) or a dilution was incubated in the waterbath to increase the 
number of bacteria. Five-fold serial dilutions were then produced from the enriched sample. 
4.5 Colony replication 
Bacterial growth on the master grid was copied onto HGMF grids on a series of nine different 
agars using an RP-1 HGMF replicator (Filtaflex, Almonte, Ontario, Canada). In order of 
replication, these agars were: Mueller-Hinton (MH) containing ceftiofur at three different 
concentrations - 4, 8 and 16 µg/ml (Northeast Laboratory Services, Waterville, ME); 
chromogenic agar (BBL Chromagar Orientation, Becton, Dickinson and Company, Franklin 
Lakes, NJ), MH agar containing either ampicillin (16 µg/ml), tetracycline (8 µg/ml), 
sulfamethoxazole (256 or 512 µg/ml), or chloramphenicol (16 µg/ml) (Northeast Laboratory 
Services, Waterville, ME); and MH plates without an added antimicrobial agent (Northeast 
Laboratory Services, Waterville, ME) to ensure that the inoculum was transferred to all agar 
plates. All plates were incubated at 37°C for 18-24 hours. The chromogenic media served as a 
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control for E. coli (purple appearance). 
Breakpoints were adopted from the Clinical and Laboratory Standards Institute (CLSI, 2008). 
The presence of the blaCMY-2 gene, which has been linked to ceftiofur resistance in Salmonella 
isolates, is strongly associated with a minimal inhibitory concentration of 8 µg/ml (Alcaine et 
al., 2005).  
The concentration of sulfamethoxazole was switched from 256 µg/ml to 512 µg/ml after the 
beginning of the study; information for this antimicrobial is therefore incomplete and was 
excluded.  
4.6 Quality control 
Identity of E. coli was confirmed for a subset of typical purple-colored isolates on 
chromogenic agar either in the Animal Health Diagnostic Center (AHDC), Cornell University 
College of Veterinary Medicine or by the Sulfide Indole Motility (SIM) tube test. To ensure 
quality of the filter system, two E. coli isolates were chosen as positive and negative controls. 
These were cultured, processed and replicated as described for replicate samples from study 
animals. The isolate serving as negative control (ATCC 25922) was confirmed to be 
susceptible to all study antimicrobials using the Sensititre Automated Microbiology System´s 
A80 Panel (TREK Diagnostic Systems Inc., Cleveland, OH) in the AHDC. The positive 
control, originating from a previous study, was characterized as multi-drug resistant by the 
same method and as having the blaCMY-2 gene by PCR. For quality control of the plates and 
growth conditions, both isolates were streaked onto the side of the antimicrobial plates, 
outside the grid zone, for at least two sample days per cow.  
4.7 Imaging and analysis of colony growth 
Digital pictures of HGMF filters on agar were taken with a camera (Canon Power Shot SX110 
IS) using remote picture software to enhance quality (PSRemote Version 1.6.4, Breeze 
Systems Limited, Bagshot, Surrey, UK). Customized software for image analysis 
(HGMFRES, NSW Department of Primary Industries, Wollongbar, NSW, Australia) was then 
used to detect bacterial growth and identify the grid cell address (row and column position) of 
each colony as described previously. (Jordan et al., 2005). A third software (HGMF Image 
Dr, NSW Department of Primary Industries, Wollongbar, NSW, Australia) was used to 
exclude all colonies on the chromogenic agar not showing the typical E. coli color reaction.  
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4.8 Statistical analysis 
Data were analyzed using SAS ver. 9.1 (SAS Institute Inc., Cary, NC, USA). The distribution 
of parity and days in milk among treatment groups was analyzed using Kruskal-Wallis tests. 
The pairwise associations of reduced susceptibility to tetracycline, ampicillin and ceftiofur 
were analyzed at the isolate-level using chi-squared tests and at the cow-level using 
Spearman´s rank correlation. Estimation of E. coli concentrations in fecal samples was 
achieved by applying the following formula: 
 
 
 
where n is the count of isolates on the control grids, dil is the number of five-fold dilutions to 
reach the solution providing approximately 50-150 isolates per grid, and the other values 
represent volumes transferred in the various steps of the procedure. In the case of enriched 
samples dilution number was set to 0. Repeated measures analysis of variance (ANOVA; 
PROC MIXED) was used to analyze the treatment group effect on the log10 concentration 
over time. Cow was treated as a subject effect and a first-order autoregressive covariance 
structure was specified. Sample day (0, 2, 7, 14, 21 and 28) was included in the model as a 
fixed effect. The treatment by day interaction term was tested to determine whether changes 
in concentration over time depended on treatment group. Pairwise differences between 
treatment-day combinations were tested using Bonferroni-corrected p-values. Assessment of 
the normality of model residuals and plots of residual values against predicted values were 
used to evaluate model assumptions and were considered acceptable for this model. 
Treatment group effects on reduced antimicrobial susceptibility were analyzed by first 
calculating the proportion of isolates with growth on the applicable antimicrobial plate among 
those grid cells with growth on both on the MH and chromogenic agar control plates. This 
was done for each cow-sample day combination. For each combination of antimicrobial and 
drug-concentration, the change from the pre-treatment measurement in proportion reduced 
susceptibility was calculated within cow for each post-treatment day. The data were analyzed 
initially using repeated measure ANOVA as described above, but model assumptions were 
not met. Therefore Kruskal-Wallis tests were used to compare treatment groups on each 
sample day. The effect was also evaluated by calculating the maximum change from baseline 
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for each drug for each cow. The effect of treatment group, days in milk at enrollment, 
lactation group (1, 2 or ≥3), and breed on maximum change were evaluated using Kruskal 
Wallis tests.  
5 Results 
Of 44 animals enrolled, 2 were excluded because of sale or treatment changes (Table 1). The 
animals retained in the study included 32 Holstein-Friesians and 10 Ayrshires. All except two 
cows were enrolled within 14 days after calving. None of the cows received systemic 
antimicrobial treatment directly prior to enrollment, but one animal started in the study one 
week after dry treatment. One cow received ceftiofur for six days, another cow was treated 
with oxytetracycline starting 8 days after treatment with ceftiofur was completed. These were 
not excluded from the analysis. 
A total of 240 individual fecal samples and 21983 E. coli isolates were included in the 
statistical analysis. The distribution of isolates between the treatment groups was 7,237, 8,222 
and 6,524 for ceftiofur, control and penicillin, respectively, and there was approximately even 
distribution of isolates across sample days. There were no significant differences in days in 
milk (DIM) or lactation number between treatment groups (p>0.15). The median and mean 
true sample intervals are displayed in Table 2. The median number of isolates from each 
sample was 82 and ranged from 21 to 238. Quality control measures for laboratory outcomes 
were all consistent with the expected results except that a concentration problem was detected 
with some chloramphenicol plates which lead us to exclude those data from the analysis. 
5.1 Effect of antimicrobial treatment on E. coli concentration 
Information about dilution was missing for eight samples and calculations were therefore 
based on 232 samples. A significant effect of ceftiofur treatment on E. coli concentration in 
the feces as estimated by dilution number was detected. The repeated measure ANOVA 
treatment by day interaction was significant (p < 0.0001). Based on pairwise comparisons, 
this effect was due to a significant decrease in concentration for samples collected on days 2 
and 7 from cows in the ceftiofur group, but we also noted a moderate increase in estimated 
cfu on day 7 in the penicillin group (Figure 2). Because of arbitrary assignment of a dilution 
of 0 to 15 samples requiring enrichment, this analysis was also checked using a non-
parametric rank-based method. This confirmed significant differences among treatment 
groups on day 2 and 7. Ten of these 15 were from ceftiofur-treated cows on days 2, 7 and 14. 
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5.2 Prevalence of isolates with RS to antimicrobials 
The percentages (95% confidence intervals in parentheses) of RS isolates at day of enrollment 
were 3.0% (2.5, 3.6) for ampicillin, 10.6% (9.7, 11.6) for tetracycline and 4.8% (4.2, 5.6) for 
4 µg/ml ceftiofur (cef 4); 1.7% (1.3, 2.1) showed ceftiofur resistance with growth at 8 µg/ml 
ceftiofur (cef8) and 0.7% (0.4, 1.0) for 16 µg/ml ceftiofur (cef16). Growth on two or more 
antimicrobial plates was found for 1.5% (1.1, 1.9) of isolates. Differences in percentage of 
growth between herds at enrollment were significant for tetracycline, cef4 and cef8 as listed in 
Table 3. For all sample dates combined, of the 21983 E. coli isolates, 1.8% (1.6, 1.9), 12.6% 
(12.2, 13.1), 4.0% (3.7, 4.2), 0.9% (0.8, 1.0) and 0.3% (0.2, 0.4) exhibited growth on 
ampicillin, tetracycline, cef4, cef8 and cef16 respectively. Growth on two or more plates was 
found for 1.8% (1.6, 1.9) of isolates and the percentage of isolates growing on at least one of 
the antimicrobial agar plates was 16.9% (16.4, 17.4). 
Isolates showing RS or resistance to ceftiofur were significantly more likely to show RS to 
ampicillin or tetracycline (p<0.0001). Isolates growing on cef16 were significantly more 
likely to also grow on cef8 or cef4 (relative risk (RR) 125.5 and 19.8 respectively) and the 
same was true for isolates growing on cef8 to also grow on cef4 (RR 17.6). Isolates growing 
on tetracycline plates were significantly more likely to also grow on ampicillin (RR 3.3) and 
the reverse situation had an even more pronounced effect (RR 4.6). RS or resistant ceftiofur 
isolates were more likely to show RS to ampicillin (RR 2.6), whereas there was a weaker 
association with tetracycline RS (RR 1.4). All RR had a p-value <0.0001 in isolate-level 
analyses. 
5.3 Effect of antimicrobial treatment on susceptibility of E. coli 
The Kruskal-Wallis test for individual treatment days was significant only for the change in 
tetracycline susceptibility on day 2 (p-value =0.01) with the ceftiofur treated group having the 
largest increase from baseline, penicillin treated cows intermediate and the control group the 
lowest. The change in the proportion isolates growing on cef16 followed a similar pattern, 
though less significant (p-value = 0.1) because of increases from day 0 to day 2 in three cows 
in the ceftiofur group. The proportion growth at a concentration of 16 μg/ml ceftiofur for 
these three cows increased from 2 to 8%, 0 to 14%, and 0 to 6%, respectively, and were 0% 
on all sampling days thereafter. There were no significant differences in maximum change 
from baseline among treatment groups (p ≥ 0.15). Additionally, neither DIM at enrollment (0-
7, with >7 set equal to 7), lactation group (1, 2, 3 or greater), nor herd had a significant effect 
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on the maximum change from baseline (≥ 0.19). 
No significant changes were found in the susceptibility of isolates from untreated control 
cows that were enrolled paired with treated cows and sampled on the same schedule. 
5.4 Individual cow and herd effect 
Cow-level average percentages of RS and resistance for each antimicrobial drug are displayed 
in Figure 3. The proportion of isolates showing RS was highly variable among cows with a 
few cows yielding a high percentage of RS isolates across multiple sampling days. In cow-
level analyses, parity, DIM and breed did not have statistically significant effects on 
maximum change in susceptibility of E. coli isolates (p>0.05). 
6 Discussion 
The reduction in the concentration of E. coli in fecal samples during systemic treatment with 
ceftiofur found in day 2 and day 7 samples is consistent with previous reports (Jiang et al., 
2006; Singer et al., 2008; Daniels et al., 2009) and signifies a very large selection pressure 
induced by the presence of the drug.  
The frequency of isolates with reduced susceptibility found in our study population was equal 
to or less than the percentage of resistant E. coli isolated from dairy herds using conventional 
production methods in the United States previously reported by DeFrancesco et al. (2004), 
Sato et al. (2005) and Lundin et al. (2008). However, the observation that certain cows shed 
much higher levels of reduced susceptible E. coli isolates warrants further investigation to see 
if this is a permanent or transient biological effect.  
We did not find a significant change in ceftiofur susceptibility among E. coli isolates during 
or after treatment with ceftiofur. This may be due to several factors. First, the emergence and 
spread of resistance under selection pressure might be such a rare event that even our study 
design, which targeted a large number of isolates per sample and used repeated sampling as 
well as control animals, was unable to detect it. This would be consistent with Tragesser et al. 
(2006) finding a herd-level but not an individual-cow effect in a study investigating ceftiofur 
use and isolation of E. coli with RS to ceftriaxone. Second, the number of ceftiofur-resistant 
E. coli in the population before treatment might determine the amount of change observed 
after treatment. Lowrance et al. (2007) reported a transient increase in the population of 
ceftiofur-resistant isolates in a cohort study of feedlot cattle treated with ceftiofur crystalline-
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free acid. Systemic treatment with ceftiofur may allow E. coli isolates already in possession of 
resistance genes to temporarily dominate the intestinal flora while proportionally killing larger 
numbers of susceptible strains. Although the proportion of E. coli with RS to ceftiofur did not 
increase significantly in our study during or after treatment, the percentage of isolates with 
resistance to ceftiofur (16µg/ml) tended to be higher in day 2 samples when the E. coli 
concentration was greatly reduced. 
An advantage of this study was the ability to repeatedly test a relatively large sample of the 
gut E. coli population for traits of resistance and reduced susceptibility following 
antimicrobial therapy. Although our study design allowed for good estimates of the proportion 
resistant isolates in each sample, we recognize that having a sample size of about 14 cows per 
group and reliance on nonparametric statistical methods may have limited the study power for 
detecting differences among treatments. 
7 Conclusions 
In this study, most E. coli isolates were susceptible to all antimicrobials tested; however, there 
was wide cow-to-cow variation of antimicrobial susceptibility within the E. coli population. 
Ceftiofur treatment significantly reduced the concentration of fecal E. coli for several days 
after treatment, but the proportion of isolates susceptible to ampicillin, tetracycline or 
ceftiofur was largely unaffected except for a change in tetracycline resistance noted in the 
ceftiofur-treated group on day 2. The large number of isolates evaluated provided a high 
probability of detecting major effects of ceftiofur treatment on fecal E. coli antibiotic 
susceptibility in the treated cows. The population dynamics of intestinal microbial flora is 
complex and unmeasured factors may account for differences among studies evaluating 
antimicrobial drug treatment effects on the emergence of resistance.   
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10  Tables and Figures 
 
Figure 1. Typical master grid on MacConkey agar: Escherichia coli growth within grid cells 
on the hydrophobic grid membrane filter (red appearance).  
 
Table 1. Descriptive statistics of the 42 cows included in the analysis by herd. 
 
 
 
 
 
 
 
 
 
 
 Herd A Herd B 
Total number of cows 27 15 
Total number of E. coli isolates 11435 6702 
Number of animals treated for metritis 17 9 
Number of animals treated for interdigital necrobacillosis 0 1 
Median lactation number (min-max) 2 (1-5) 1 (1-5) 
Median days in milk (min-max) 2 (0-5) 8 (0-282) 
Number of animals enrolled in ceftiofur group 9 5 
Number of animals enrolled in penicillin group 8 5 
Number of animals enrolled in control group 10 5 
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Table 2. Comparison between the target number of days between sampling events 
and the actual number of days between sampling given as median, minimum, 
maximum and mean. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
Actual sample interval (days) 
Sampling event Target sample  
interval (days) 
Median (min - max) 
 
Mean 
    
Day 0 0 0 (0-0) 0 
Day 2 2 2 (1-5) 2.3 
Day 7 5 5 (3-7) 4.8 
Day 14 7 7 (5-8) 7.0 
Day 21 7 7 (3-7) 6.8 
Day 28 7 7 (4-8) 6.8 
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Figure 2. Effect of treating dairy cows with ceftiofur as compared to treatment with penicillin 
or no treatment (control) on the mean concentration of fecal Escherichia coli concentration 
(cfu/g) over time. Data obtained as predictions from linear mixed models with error bars 
representing approximate 95% confidence interval for the mean effects. 
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Table 3. Percentage of fecal Escherichia coli isolates at day of enrollment with reduced 
susceptibility to ampicillin (Amp), tetracycline (Tet) or ceftiofur (Cef). P-values are 
calculated for differences between farm A and B. P-values test for the hypothesis that 
percentage of reduced susceptible isolates from Farm A ≠ Farm B for each antimicrobial. 
 
 
Figure 3. Box and whiskers plots of the cow-level percentages of Escherichia coli isolates 
growing on plates containing antimicrobial agents (n=42 cows). Amp=ampicillin (16 μg/ml), 
Cef4 = ceftiofur (4 μg/ml), Cef8 = ceftiofur (8 μg/ml), Cef16 = ceftiofur (16 μg/ml) and Tet = 
tetracycline (8 μg/ml).
Percentage of isolates 
 Farm A Farm B Combined P-value 
     
Amp 16µg/ml 3.1 2.8 3.0 0.65 
Tet 8 µg/ml 12.5 6.7 10.6 <0.0001 
Cef 4 µg/ml 6.5 1.4 4.8 <0.0001 
Cef 8 µg/ml 2.3 0.3 1.7 <0.0001 
Cef 16 µg/ml 0.9 0.2 0.7 0.019 
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IV DISCUSSION 
Several effects of antimicrobial drug use on a given strain of bacterial population are possible. 
A population of bacteria that is fully susceptible to a bactericidal drug will react to the 
application of the drug with a significant reduction in the total number of bacteria, although in 
some cases a minimal subpopulation may remain. This effect can be achieved by careful 
choice of drug, identification of the bacterial population targeted, susceptibility testing prior 
to treatment and sufficient dosage, adequate route of administration and length of therapy.  
In circumstances where bacteria that are intrinsically resistant or resistance to the particular 
drug in the population has been uniformly established previously, bacterial population 
dynamics will most likely not be altered after exposure to an antimicrobial agent for which 
resistance is ubiquitous in the population. 
When a drug is used and a mixed population of target bacteria containing resistant and 
susceptible strains is present, exposure of this population may lead to the disappearance of the 
susceptible strains, leaving those, that are in possession of resistance-encoding genes towards 
the drug, without changing the total number of those bacteria. If this situation is present, 
resistant bacteria will be found more frequently during the course of treatment, yet the drug 
did not have an effect on the resistant strain itself and the total number of bacteria will be 
greatly reduced during and possibly for some time after treatment is completed. 
Another possibility when antimicrobial selection pressure acts on a mixed population of 
bacteria is a net gain in total number of resistant bacteria during the reduction of susceptible 
strains. This may be due to spread of resistance encoding genes to susceptible bacteria under 
the influence of the antimicrobial or to the enhancement of growth of resistant strains. The 
total size of the population may or may not be reduced depending on the rise in number of 
resistant bacteria. 
Even when the guidelines for prudent antimicrobial use are heeded, and a population of 
uniformly susceptible bacteria is opposed to the drug, the effect of selection pressure can lead 
to the emergence of resistance. Bacteria can gain resistance either through mutation or more 
likely through horizontal gene transfer from different bacteria that share the same 
environment and are able to exchange genetic material with the target species. Treatment will 
therefore potentially result in induction of resistance or more likely the spread of resistance 
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not only to the target bacteria but to other bacterial populations as well. 
All these different scenarios of antimicrobial drugs acting on bacterial populations are 
theoretically possible and in a real-life situation where different bacteria and different strains 
are abundant, we will most likely find a mixture of all of the above.  
The results of our study indicated that in the case of exposure of fecal E. coli isolates to 
ceftiofur, the most prominent measurable effect was the reduction of total size of the 
population, making it more likely to find resistant bacteria. We were not able to document the 
effects of induction of resistance and net gain in resistant population with the study design 
that was applied. However, this does not mean that they did not occur at levels undetectable 
by the study methods. 
Studies similar to the one we carried out have found similar effects of ceftiofur use on the 
fecal E. coli population while others reported a net increase in resistant isolates or found a 
combination of both effects (Jiang et al., 2006; Tragesser et al., 2008; Lowrance et al., 2007; 
Singer et al., 2008; Alali et al., 2009). It is important to mention that protocols varied greatly 
between the different investigations. Singer et al. (2008) studied the effect of ceftiofur 
treatment in dairy cattle and found a significant drop in total fecal E. coli bacterial counts in 
ceftiofur treated animals (n=5). The authors reported that the ceftiofur-resistant bacterial 
population did not increase in quantity when treating cows with ceftiofur but that “levels 
stayed low and were overtaken by a returning susceptible population”. While the effect of 
significant reduction of E. coli concentration in feces was also described by Lowrance et al. 
(2007) studying feedlot cattle, the authors stated that administration of ceftiofur crystalline-
free acid (CCFA, a long-acting formulation of ceftiofur used as a “one-shot therapy”) leads to 
a “detectable selection pressure within the gastrointestinal tract that favored transient 
expansion of ceftiofur resistance” in the E. coli isolates that were tested. In this study as well 
as in the previously mentioned study by Singer et al. (2008), susceptibility testing was only 
performed on a subset of three colonies per fecal sample. Tragesser et al. (2006) compared E. 
coli fecal isolates with reduced susceptibility to ceftriaxone in herds for which ceftiofur use 
was reported with herds where ceftiofur was not used and found a significant correlation of 
ceftiofur use and the existence of cows on a farm from which ceftriaxone-resistant E. coli 
were isolated. This herd-level association was not confirmed at the individual cow level, 
where “…no association was found between receiving ceftiofur in the previous six months 
and the isolation of E. coli with reduced ceftriaxone susceptibility.” 
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Another study investigated the effect of three different doses of ceftiofur (in the form of 
CCFA) given to beef feedlot cattle on the quantity of a gene encoding for ceftiofur resistance 
(blaCMY-2) compared to a standardized reference gene (16SrRNA) among total community 
DNA extracted from fecal samples (Alali et al., 2009). The authors concluded that “the 
administration of CCFA in feedlot cattle may provide selection pressure favoring higher 
levels of blaCMY-2 carriage, but this may lead to concurrent reductions in the total bacterial 
population (as reflected by lowered 16srRNA) during the treatment period.” 
The effect of ceftiofur treatment on fecal bacteria has also been investigated in dairy calves. 
Jiang et al. (2006) showed that total bacterial counts in feces were reduced following the first 
dose of antibiotic treatment and that immediately after treatment the means of ceftriaxone-
resistant bacterial counts increased by 1.05, 0.87, or 0.58 log CFU/g for three different 
ceftriaxone concentrations used (16, 64, or 128 μg/ml) which the authors concluded 
“…revealed that the treatment of calves with ceftiofur can temporarily change the bacterial 
flora in the calf´s intestine to favor the growth of ceftriaxone-resistant fecal bacteria.” 
In conclusion it seems that while most authors that investigated the effect of ceftiofur on the 
fecal bacterial population documented a reduction in total bacterial E. coli counts, the effect 
of a (transient) net increase in resistant bacteria was not found in all studies.  
One of the main differences in our study compared to the investigations described above was 
that we used a treatment protocol that is often applied in dairy practice with a four-day 
treatment period. This differed from other studies in that treatment was one day shorter 
(Singer et al., 2008) or that no long-acting preparation of ceftiofur (CCFA) was used 
(Lowrance et al., 2007; Alali et al., 2009). 
In interpreting the results of this investigation, it is important to recognize that ceftiofur was 
generally used on both farms prior to this study and that each cow was sampled over a period 
of four weeks. It could be expected that results are possibly different when introducing a new 
drug into a population or even when studying fecal populations for a longer period of time. 
Cows with clinical metritis and interdigital necrobacillosis were enrolled because these are 
common indications for ceftiofur use (Chenault et al., 2004) and the study was conducted in a 
real-life situation in commercial dairy herds. Penicillin is a frequently used alternative to 
ceftiofur when treating those two diseases and was therefore chosen for the second treatment 
group. We did not expect penicillin to influence the E. coli population significantly because 
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penicillin acts on the bacterial cell wall synthesis of Gram-positive organisms. But by using a 
treatment control group we were able to eliminate the possibility that disease was a significant 
factor on the recovery of resistant fecal E. coli isolates. This was important since the third 
group, the non-treated controls, consisted of healthy cows only.  
In our study, the amount of drug was the same for all animals regardless of their actual body 
weight to be consistent with usual practices on the participating farms. By not measuring the 
actual weight of each individual cow, one can argue that some animals might have received a 
higher dose than others. All animals enrolled in the study received a dose in the range 
indicated on the label instructions (Excenel RTU, ceftiofur hydrochloride, 0,5-1mg/kg, 1-2 
ml/100 lbs body weight [1-2ml/45 kg] for 3-5 consecutive days, (Pfizer, 2008). Because we 
applied the same treatment protocol to all cows being sequentially enrolled we believe that we 
did not produce a bias and if dose-dependent effects occurred they would have been evenly 
distributed among both treatment groups. 
When estimating E. coli cfu/g in fresh fecal matter, we did not consider the possible 
differences in dry matter which might have differed between individuals and between 
sampling days. The water content of dairy cow feces usually lies within a range of 79 to 83 % 
(Shalit et al., 1991) and is typically 81,2 % in fresh samples (Wang et al., 1996), but the 
moisture content can vary as much as 70 to 85 % (Murphy, 1992). Although we did not 
account for this possible variation, the results of the estimated cfu/g were of a much higher 
magnitude (maximum reduction of colony size by the factor 10
-3 
on day 2 of ceftiofur 
treatment) than can be explained by the relatively small potential difference in water content.  
Although our design setup may have had the above mentioned flaws, we believe that there is 
value in the study results. To our knowledge it is the first investigation on the effect of 
ceftiofur treatment compared to two control groups on large numbers of E. coli isolates by 
using the HGMF method. We confirmed the findings of other studies documenting the strong 
effect of reducing total fecal E. coli population. When looking at the percentage of resistant 
isolates in a sample, we did not detect an increase in those isolates as a proportion of total E. 
coli detected. The population dynamics are altered by many factors, making it impossible to 
guarantee equal sampling conditions over time. Nevertheless, when looking at the results of 
our study we must conclude that if ceftiofur use leads to the spread and emergence of 
resistance in fecal E. coli isolates in dairy cows under field conditions, this must be a rare 
event which we were not able to document. 
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V SUMMARY 
The existence of resistance mechanisms of bacteria against the action of antimicrobial drugs is 
a well documented fact and has complicated treatment of bacterial disease since the beginning 
of antimicrobial therapy in the last century.  
Drug resistance is a problem of veterinary and human medicine alike, especially when 
considering infections with food-borne pathogens such as Salmonella. Fecal E. coli isolates 
were used as a model to measure the effect of treating dairy cows systemically with ceftiofur 
on antimicrobial resistance of this important pathogen. Ceftiofur, a third-generation 
cephalosporin, is an attractive treatment for certain diseases in dairy cattle such as metritis and 
interdigital necrobacillosis since withholding times for meat are short and milk does not need 
to be withheld from marketing. Third-generation cephalosporins are also used in human 
medicine, for example in the treatment of systemic non-typhoidal salmonellosis in children. 
Therefore, the emergence and spread of resistance towards this class of antimicrobials has 
been a focus of concern. 
Effects of ceftiofur treatment on a group of cattle were compared to a penicillin treated group 
and a healthy control group not receiving treatment. Reduction of susceptibility of E. coli was 
tested for ampicillin, tetracycline and three different concentrations of ceftiofur. A significant 
decrease in the concentration of fecal E. coli on days 2 and 7 post-treatment was detected in 
animals treated with ceftiofur. Treatment did not have a significant effect on the proportion of 
isolates expressing reduced susceptibility to ceftiofur. The result of the reduction of total E. 
coli count in the samples during and after ceftiofur use is consistent with results reported by 
other authors. The large number of isolates analyzed provided a high possibility of detecting 
major effects of ceftiofur treatment on E. coli susceptibility. However we did not observe a 
net increase in reduced susceptible E. coli isolates with the exception of decreased 
tetracycline susceptibility in the ceftiofur treated group on day 2. 
The results of this work lead to the conclusion that the emergence and spread of resistance-
encoding genes in a bacterial population under the influence of ceftiofur are rare and that the 
effect could not be measured even though we were able to draw information on a large 
number of isolates analyzed compared to other investigations previously published on this 
topic. 
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The results are applicable to commercial dairy herds with typical antimicrobial treatment 
practices comparable to those used in the US, including prior use of ceftiofur for treating 
individual sick animals. 
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VI ZUSAMMENFASSUNG 
Das Wissen über das Vorhandensein von bakteriellen Resistenzmechanismen ist so alt wie die 
Entdeckung der Wirksamkeit antimikrobieller Substanzen. Diese Resistenzen führen seit der 
Einführung ihres Gebrauches zur Therapie menschlicher und tierischer bakterieller 
Erkrankungen im letzten Jahrhundert immer öfter zu einer Reduktion des Therapieerfolges. 
Antibiotikaresistenz ist ein Problem der Veterinär- und Humanmedizin gleichermaßen, 
besonders wenn es um Infektionen mit durch Nahrungsmittel übertragene Erreger wie 
beispielsweise Salmonellen geht. Der Effekt, den die systemische Behandlung von 
Milchkühen mit Ceftiofur auf die Resistenzlage dieses wichtigen Erregers haben könnte, 
wurde modellhaft anhand fäkaler E. coli-Bakterien untersucht. Ceftiofur gehört zur Klasse der 
dritten Generation der Cephalosporine und ist ein häufig verwendetes Medikament für 
bestimmte bakterielle Erkrankungen von Milchkühen, wie z.B. Metritis und interdigitale 
Nekrobazillose, da die Wartezeit auf Fleisch kurz ist und die Milch trotz antibiotischer 
Behandlung der Kuh abgeliefert werden kann. Cephalosporine der dritten Generation werden 
auch in der Humanmedizin angewandt, zum Beispiel für die Behandlung systemischer 
Infektionen mit nicht-typhoiden Salmonellen beim Kind. Aufgrund dieser Tatsache gibt die 
Enstehung und Verbreitung von Resistenzen gegenüber dieser Klasse von Antibiotika Anlass 
zur Sorge. 
Gemessen wurde der Effekt der systemischen Behandlung von kranken Tieren mit Ceftiofur 
im Vergleich zur Behandlung einer Gruppe erkrankter Kühe mit Penicillin und einer 
unbehandelten, gesunden Kontrollgruppe auf die reduzierte Wirkung von Ampicillin, 
Tetrazyklin und drei verschiedenen Dosierungen von Ceftiofur gegenüber fäkalen E. coli-
Bakterien. Ein signifikanter Abfall in der E. coli-Konzentration an den Probentagen 2 und 7 
nach Behandlungsbeginn konnte festgestellt werden. Die Behandlung hatte keine statistisch 
signifikanten Auswirkungen auf den Anteil der Isolate mit reduzierter Wirkung gegenüber 
Ceftiofur. Das Ergebnis der verringerten Menge an fäkalen E. coli-Bakterien während und 
nach der Gabe von Ceftiofur stimmt mit Ergebnissen anderer Autoren überein. Die 
Wahrscheinlichkeit, mit der bedeutende Effekte der Ceftiofurgabe auf die Wirksamkeit der 
getesteten Antibiotika zu messen sind, wurde durch die große Menge an Isolaten, die zur 
Analyse herangezogen werden konnte, erhöht. Abgesehen von einer transienten Zunahme der 
E. coli-Bakterien am Tag 2, die eine Resistenz gegenüber Tetrazyklin aufwiesen, konnte keine 
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Erhöhung des Anteils an Bakterien mit erhöhter Resistenz nachgewiesen werden.  
Die Ergebnisse dieser Arbeit lassen den Schluss zu, dass die Enstehung eines Resistenzgenes 
und dessen Verbreitung in der Bakterienpopulation unter dem Einfluss von Ceftiofur mit 
hoher Wahrscheinlichkeit seltene Ereignisse sind, so dass es auch durch Untersuchungen wie 
diese, der eine im Vergleich zu anderen wissenschaftlichen Studien ungleich größere Menge 
an untersuchten Isolaten zu Grunde liegt, nur schwer nachweisbar ist. 
Die Resultate der Studie gelten für solche Milchviehherden, in denen der Antibiotikaeinsatz 
dem typischen Gebrauch in den USA gleicht und in denen Ceftiofur routinemäßig für die 
Behandlung von Einzeltiererkrankungen eingesetzt wird. 
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VII ANNEX 
1 Unabridged materials and methods section 
Study population and design- We enrolled cows from two New York State dairy herds in a 
longitudinal controlled trial. Herd sizes were 140 and 300 milking cows. The dominant breed 
was Holstein-Friesian; all other cows were Ayrshires. A herd survey filled out by the owners 
showed that antimicrobial usage practices for these herds were similar to those reported for 
conventional farms by Zwald et al. (2004). Ceftiofur was used on both farms prior to the 
study for typical purposes such as treatment of respiratory disease, metritis, placental 
retention, and foot problems. Lactating cows with metritis or interdigital necrobacillosis as 
identified by the herd owner or veterinarian were enrolled sequentially in one of two 
treatment groups; ceftiofur or penicillin. The treatment for the first animal within each herd 
was selected at random. Healthy animals served as untreated controls and were paired with 
antibiotic-treated animals, alternating groups, and matching calving date and parity whenever 
possible. 
Samples were collected from each animal at enrollment (day 0) and subsequently five times in 
a four-week period. The target sampling days were 2, 7, 14, 21 and 28 days after enrollment. 
The study was conducted between July, 2008 and July, 2009. 
Treatment protocol- Treatment for cows in the ceftiofur group consisted of a subcutaneous 
injection of 1 gram of ceftiofur hydrochloride suspension (Excenel RTU, Pharmacia & 
Upjohn Co, Division of Pfizer Inc, New York, NY) once per day for a total of four days. 
Cows enrolled in the penicillin group received 9 million IU of a penicillin G procaine 
suspension (PenOnePro, Vet One, MWI, Meridian, ID) intramuscularly once per day for a 
total of four days.  
Sample collection and processing- Fecal samples were collected before treatment by the 
herd owner or veterinarian (day 0) and on days 2, 7, 14, 21 and 28 after enrollment by the 
veterinarian. Approximately 50 g of feces were collected directly from the rectum of each 
cow with a clean plastic sleeve. Samples were placed immediately into a sterile sample 
container and transported refrigerated to the laboratory to be processed on the day of 
collection.  
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Those administering treatments and collecting samples were not blinded to treatment group. 
Study personnel carrying out laboratory procedures were unaware of the assignment of 
animals. 
Fifteen g of fecal material from each sample were placed in a sterile Whirl-Pak filter bag 
(Nasco, Fort Atkinson, WI) and mixed with 40ml of a sterile 0.9% saline solution. The sample 
was then mixed in a stomacher for 2 minutes. The filtrate was placed in a second sterile 
Whirl-Pak filter bag and processed for another 2 minutes. Five 1 ml replicates of the specimen 
were aseptically transferred from the filter pocket into 5 ml freezer vials prepared with 1 ml of 
glycerol (Fisher Scientific, Fair Lawn, NJ) and tryptose soy broth (Becton, Dickinson and 
Company, Franklin Lakes, NJ) (1:1 vol/vol) and placed in a -80°C freezer for storage. 
Production of hydrophobic grid membrane filter (HGMF) master grids- HGMF master 
grids were used to enumerate and replicate bacteria using a modification of a method 
described previously (Dunlop et al., 1998; Jordan et al., 2005). A master grid containing no 
more than 200 colonies was chosen to limit the probability of any one colony being derived 
from more than one bacterium (Jordan et al., 2005). 
To generate a master grid, each frozen sample was thawed in a 30 °C water bath. Five-fold 
serial dilutions were made in 0.1 % peptone water containing 1% Tween 80 (Fisher Scientific, 
Fair Lawn, NJ). Approximately 1.5 ml of each diluted sample was filtered through a sterile 
HGMF grid (ISO-GRID®, QA Life Sciences, CA) using an SF-1 Spreadfilter (Filtaflex, 
Almonte, Ontario, Canada). 
HGMF grids were then aseptically transferred onto MacConkey agar (MAC) (Northeast 
Laboratory Services, Waterville, ME) and incubated at 37°C for 18-24 h to produce a master 
grid.   
If the dilution process failed to produce a grid as described, another replicate of the sample 
was chosen, thawed and more extended dilutions carried out until the condition was met. In 
cases where the diluted sample yielded very low numbers of colonies, either the sample was 
enriched in GN broth (Hajna) or a dilution was incubated in the waterbath to increase the 
number of bacteria. Five-fold serial dilutions were then produced from the enriched sample. 
Colony replication-Bacterial growth on the master grid was copied onto HGMF grids on a 
series of nine different agars using an RP-1 HGMF replicator (Filtaflex, Almonte, Ontario, 
Canada). In order of replication, these agars were: Mueller-Hinton (MH) containing ceftiofur 
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at three different concentrations - 4, 8 and 16 µg/ml (Northeast Laboratory Services, 
Waterville, ME); chromogenic agar (BBL Chromagar Orientation, Becton, Dickinson and 
Company, Franklin Lakes, NJ), MH agar containing either ampicillin (16 µg/ml), tetracycline 
(8 µg/ml), sulfamethoxazole (256 or 512 µg/ml), or chloramphenicol (16 µg/ml) (Northeast 
Laboratory Services, Waterville, ME); and MH plates without an added antimicrobial agent 
(Northeast Laboratory Services, Waterville, ME) to ensure that the inoculum was transferred 
to all agar plates. All plates were incubated at 37°C for 18-24 hours. The chromogenic media 
served as a control for E. coli (purple appearance). 
Breakpoints were adopted from the Clinical and Laboratory Standards Institute (CLSI, 2008). 
The presence of the blaCMY-2 gene, which has been linked to ceftiofur resistance in Salmonella 
isolates, is strongly associated with a minimal inhibitory concentration of 8 µg/ml (Alcaine et 
al., 2005).  
The concentration of sulfamethoxazole was switched from 256 µg/ml to 512 µg/ml after the 
beginning of the study; information for this antimicrobial is therefore incomplete and was 
excluded.  
Quality control-Identity of E. coli was confirmed for a subset of typical purple-colored 
isolates on chromogenic agar either in the Animal Health Diagnostic Center (AHDC), Cornell 
University College of Veterinary Medicine or by the Sulfide Indole Motility (SIM) tube test. 
To ensure quality of the filter system, two E. coli isolates were chosen as positive and 
negative controls. These were cultured, processed and replicated as described for replicate 
samples from study animals. The isolate serving as negative control (ATCC 25922) was 
confirmed to be susceptible to all study antimicrobials using the Sensititre Automated 
Microbiology System´s A80 Panel (TREK Diagnostic Systems Inc., Cleveland, OH) in the 
AHDC. The positive control, originating from a previous study, was characterized as multi-
drug resistant by the same method and as having the blaCMY-2 gene by PCR. For quality 
control of the plates and growth conditions, both isolates were streaked onto the side of the 
antimicrobial plates, outside the grid zone, for at least two sample days per cow.  
Imaging and analysis of colony growth-Digital pictures of HGMF filters on agar were taken 
with a camera (Canon Power Shot SX110 IS) using remote picture software to enhance 
quality (PSRemote Version 1.6.4, Breeze Systems Limited, Bagshot, Surrey, UK). 
Customized software for image analysis (HGMFRES, NSW Department of Primary 
Industries, Wollongbar, NSW, Australia) was then used to detect bacterial growth and identify 
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the grid cell address (row and column position) of each colony as described previously 
(Jordan et al., 2005). A third software (HGMF Image Dr, NSW Department of Primary 
Industries, Wollongbar, NSW, Australia) was used to exclude all colonies on the chromogenic 
agar not showing the typical E. coli color reaction.  
Statistical analysis- Data were analyzed using SAS ver. 9.1 (SAS Institute Inc., Cary, NC, 
USA). The distribution of parity and days in milk among treatment groups was analyzed using 
Kruskal-Wallis tests. The pairwise associations of reduced susceptibility to tetracycline, 
ampicillin and ceftiofur were analyzed at the isolate-level using chi-squared tests and at the 
cow-level using Spearman´s rank correlation. Estimation of E. coli concentrations in fecal 
samples was achieved by applying the following formula: 
 
 
 
where n is the count of isolates on the control grids, dil is the number of five-fold dilutions to 
reach the solution providing approximately 50-150 isolates per grid, and the other values 
represent volumes transferred in the various steps of the procedure. In the case of enriched 
samples dilution number was set to 0. Repeated measures analysis of variance (ANOVA; 
PROC MIXED) was used to analyze the treatment group effect on the log10 concentration 
over time. Cow was treated as a subject effect and a first-order autoregressive covariance 
structure was specified. Sample day (0, 2, 7, 14, 21 and 28) was included in the model as a 
fixed effect. The treatment by day interaction term was tested to determine whether changes 
in concentration over time depended on treatment group. Pairwise differences between 
treatment-day combinations were tested using Bonferroni-corrected p-values. Assessment of 
the normality of model residuals and plots of residual values against predicted values were 
used to evaluate model assumptions and were considered acceptable for this model. 
Treatment group effects on reduced antimicrobial susceptibility were analyzed by first 
calculating the proportion of isolates with growth on the applicable antimicrobial plate among 
those grid cells with growth on both on the MH and chromogenic agar control plates. This 
was done for each cow-sample day combination. For each combination of antimicrobial and 
drug-concentration, the change from the pre-treatment measurement in proportion reduced 
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susceptibility was calculated within cow for each post-treatment day. The data were analyzed 
initially using repeated measure ANOVA as described above, but model assumptions were 
not met. Therefore Kruskal-Wallis tests were used to compare treatment groups on each 
sample day. The effect was also evaluated by calculating the maximum change from baseline 
for each drug for each cow. The effect of treatment group, days in milk at enrollment, 
lactation group (1, 2 or ≥3), and breed on maximum change were evaluated using Kruskal -
Wallis tests.  
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2 Software analysis window 
 
Figure: HGMFRES software, NSW Department of Primary Industries, Wollongbar, NSW, 
Australia. Original digital picture of the grid to be analyzed on (left), analyzed grid with 
colonies being highlighted in red (right). 
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3 HGMF on spreadfilter device 
 
 
Figure: HGMF being placed on the SF-1 Spreadfilter (Filtaflex, Almonte, Ontario, Canada). 
The inoculum is filtered through the membrane with the help of vacuum.
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